Literature DB >> 21768188

Immunohistochemistry in the distinction between primary and metastatic ovarian mucinous neoplasms.

W Glenn McCluggage1.   

Abstract

The distinction between a primary and metastatic mucinous carcinoma within the ovary may be problematic. In most cases, the distinction can be made by careful pathological examination encompassing both the gross and microscopic findings and taking into account the distribution of the disease. However, immunohistochemistry may be of value in certain scenarios. In this review, I discuss the value of markers in the distinction between primary ovarian mucinous neoplasms and metastatic mucinous carcinomas from the colorectum, appendix, pancreas, biliary tract, stomach and cervix, the most common primary sites which give rise to metastatic mucinous carcinoma within the ovary. There is a significant degree of immunophenotypic overlap between primary ovarian mucinous neoplasms and metastatic mucinous carcinomas from the gastrointestinal tract, especially the upper gastrointestinal type; this is because most primary ovarian mucinous carcinomas and borderline tumours are of so-called intestinal or enteric type and exhibit some degree of positivity with enteric markers. Mullerian type primary ovarian mucinous neoplasms also exist and exhibit distinct immunohistochemical differences to the more common intestinal type.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21768188     DOI: 10.1136/jcp.2010.085688

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  14 in total

Review 1.  [Morphology of secondary ovarian tumors and metastases].

Authors:  L-C Horn; J Einenkel; R Handzel; A K Höhn
Journal:  Pathologe       Date:  2014-07       Impact factor: 1.011

2.  Massively parallel sequencing analysis of mucinous ovarian carcinomas: genomic profiling and differential diagnoses.

Authors:  Jennifer J Mueller; Brooke A Schlappe; Rahul Kumar; Narciso Olvera; Fanny Dao; Nadeem Abu-Rustum; Carol Aghajanian; Deborah DeLair; Yaser R Hussein; Robert A Soslow; Douglas A Levine; Britta Weigelt
Journal:  Gynecol Oncol       Date:  2018-05-22       Impact factor: 5.482

Review 3.  Prognostic biomarkers in endometrial and ovarian carcinoma.

Authors:  Xavier Matias-Guiu; Ben Davidson
Journal:  Virchows Arch       Date:  2014-02-07       Impact factor: 4.064

4.  International Study of Primary Mucinous Ovarian Carcinomas Managed at Tertiary Medical Centers.

Authors:  Jennifer J Mueller; Henrik Lajer; Berit Jul Mosgaard; Slim Bach Hamba; Philippe Morice; Sebastien Gouy; Yaser Hussein; Robert A Soslow; Brooke A Schlappe; Qin C Zhou; Alexia Iasonos; Claus Høgdall; Alexandra Leary; Roisin E O'Cearbhaill; Nadeem R Abu-Rustum
Journal:  Int J Gynecol Cancer       Date:  2018-06       Impact factor: 3.437

5.  The cytokeratin 17 expression in primary ovarian tumors has diagnostic but not prognostic significance.

Authors:  Pavel Dundr; Barbora Bazalová; Michaela Bártů; Tjalling Bosse; Jana Drozenová; Pavel Fabian; Oluwole Fadare; Jitka Hausnerová; Radek Jakša; Jan Laco; Sigurd F Lax; Radoslav Matěj; W Glenn McCluggage; Gábor Méhes; Romana Michálková; Kristýna Němejcová; Naveena Singh; Simona Stolnicu; Petr Škapa; Marián Švajdler; Ivana Stružinská
Journal:  Virchows Arch       Date:  2022-05-13       Impact factor: 4.535

6.  A combination of the immunohistochemical markers CK7 and SATB2 is highly sensitive and specific for distinguishing primary ovarian mucinous tumors from colorectal and appendiceal metastases.

Authors:  Nicola S Meagher; Linyuan Wang; Peter F Rambau; Maria P Intermaggio; David G Huntsman; Lynne R Wilkens; Mona A El-Bahrawy; Roberta B Ness; Kunle Odunsi; Helen Steed; Esther Herpel; Michael S Anglesio; Bonnie Zhang; Neil Lambie; Anthony J Swerdlow; Jan Lubiński; Robert A Vierkant; Ellen L Goode; Usha Menon; Aleksandra Toloczko-Grabarek; Oleg Oszurek; Sanela Bilic; Aline Talhouk; Montserrat García-Closas; Qin Wang; Adeline Tan; Rhonda Farrell; Catherine J Kennedy; Mercedes Jimenez-Linan; Karin Sundfeldt; John L Etter; Janusz Menkiszak; Marc T Goodman; Paul Klonowski; Yee Leung; Stacey J Winham; Kirsten B Moysich; Sabine Behrens; Tomasz Kluz; Robert P Edwards; Jacek Gronwald; Francesmary Modugno; Brenda Y Hernandez; Christine Chow; Linda E Kelemen; Gary L Keeney; Michael E Carney; Yanina Natanzon; Gregory Robertson; Raghwa Sharma; Simon A Gayther; Jennifer Alsop; Hugh Luk; Chloe Karpinskyj; Ian Campbell; Peter Sinn; Aleksandra Gentry-Maharaj; Penny Coulson; Jenny Chang-Claude; Mitul Shah; Martin Widschwendter; Katrina Tang; Minouk J Schoemaker; Jennifer M Koziak; Linda S Cook; James D Brenton; Frances Daley; Björg Kristjansdottir; Constantina Mateoiu; Melissa C Larson; Paul R Harnett; Audrey Jung; Anna deFazio; Kylie L Gorringe; Paul D P Pharoah; Parham Minoo; Colin Stewart; Oliver F Bathe; Xianyong Gui; Paul Cohen; Susan J Ramus; Martin Köbel
Journal:  Mod Pathol       Date:  2019-06-25       Impact factor: 8.209

7.  Incidence of epithelial ovarian cancer according to histologic subtypes in Korea, 1999 to 2012.

Authors:  Se Ik Kim; Myong Cheol Lim; Jiwon Lim; Young Joo Won; Sang Soo Seo; Sokbom Kang; Sang Yoon Park
Journal:  J Gynecol Oncol       Date:  2015-12-01       Impact factor: 4.401

8.  Abdominopelvic washings: A comprehensive review.

Authors:  Erika F Rodriguez; Sara E Monaco; Walid Khalbuss; R Marshall Austin; Liron Pantanowitz
Journal:  Cytojournal       Date:  2013-04-24       Impact factor: 2.091

9.  International trends in ovarian cancer incidence from 1973 to 2012.

Authors:  Wende Hao; Yue Zhang; Zhefeng Li; Enjie Zhang; Shen Gao; Chenghong Yin; Wentao Yue
Journal:  Arch Gynecol Obstet       Date:  2021-02-22       Impact factor: 2.344

10.  Trends in incidence and survival outcome of epithelial ovarian cancer: 30-year national population-based registry in Taiwan.

Authors:  Ying-Cheng Chiang; Chi-An Chen; Chun-Ju Chiang; Tsui-Hsia Hsu; Ming-Chieh Lin; San-Lin You; Wen-Fang Cheng; Mei-Shu Lai
Journal:  J Gynecol Oncol       Date:  2013-10-02       Impact factor: 4.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.